Company news
Oncodesign Precision Medicine S.A. news in 2026
Oncodesign Precision Medicine S.A.'s news releases, calls and decks from 2026, newest first.
OPM Announces Its 2026 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position
October 21, 2026
OPM Achieved Several Major Scientific and Regulatory Milestones as Part of the LARKIN Program, Supported With Funding By The Michael J. Fox Foundation for Parkinson's Research (MJFF)
October 7, 2026
OPM Announces Its 2025 Annual Results and Provides an Update on Its Clinical Developments
April 30, 2026
Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease
March 3, 2026
Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix® Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases
January 8, 2026